MedOptions is growing. The nation’s leading provider of behavioral health services to skilled nursing and assisted living facilities continues to expand and has local opportunities for nurse practitioners to join our team of 800 clinicians and support staff. MedOptions partners with skilled nursing and assisted living facilities across the nation to provide expert behavioral health services, improving the overall mental health in elderly patients through the use of memory care evaluations, medication management, and behavioral interventions. Our multidisciplinary team consists of psychiatrists, nurse practitioners, clinical psychologists and clinical social workers. They are experienced in dementia care and Alzheimer’s care, long term behavioral health care in elderly populations, and memory care services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GENAPSYS RAISES $75M TO BRING ITS TABLETOP DNA SEQUENCER TO ASIA AMID CORONAVIRUS OUTBREAK

FierceBiotech | February 06, 2020

news image

Just months after collecting $90 million to support the launch of its compact DNA sequencing hardware, GenapSys has raised another $75 million to finance its global expansion with its eyes set on the Asia-Pacific market and the expanding coronavirus outbreak. The company’s high-throughput sequencer—which sits on a tabletop and weighs less than 10 pounds—is being launched in South Korea, Singapore, Japan and China as part of more than 25 recently inked distribution deals....

Read More

Medical

IMMUNIC REPORTS POSITIVE INTERIM DATA FROM PHASE 2 CALLIPER TRIAL OF VIDOFLUDIMUS CALCIUM IN PROGRESSIVE MULTIPLE SCLEROSIS

PR Newswire | October 10, 2023

news image

Immunic, Inc. a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive interim data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). The Company believes t...

Read More

Medical

CONVATEC SELECTS VEEVA VAULT CDMS FOR STUDY OF BIOMARKERS IN WOUND INFECTIONS

Veeva Systems | September 24, 2021

news image

Veeva Systems announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic disease, has selected Veeva Vault CDMS , which will provide electronic data entry ( EDC ), coding and data cleaning for its upcoming study on wound infection detection. ConvaTec and its partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers:...

Read More

LILLY BEGINS WORLD'S FIRST STUDY OF A POTENTIAL COVID-19 ANTIBODY TREATMENT IN HUMANS

Lilly | June 01, 2020

news image

Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in just three months after AbCellera and the Vaccine Research Center at t...

Read More
news image

GENAPSYS RAISES $75M TO BRING ITS TABLETOP DNA SEQUENCER TO ASIA AMID CORONAVIRUS OUTBREAK

FierceBiotech | February 06, 2020

Just months after collecting $90 million to support the launch of its compact DNA sequencing hardware, GenapSys has raised another $75 million to finance its global expansion with its eyes set on the Asia-Pacific market and the expanding coronavirus outbreak. The company’s high-throughput sequencer—which sits on a tabletop and weighs less than 10 pounds—is being launched in South Korea, Singapore, Japan and China as part of more than 25 recently inked distribution deals....

Read More
news image

Medical

IMMUNIC REPORTS POSITIVE INTERIM DATA FROM PHASE 2 CALLIPER TRIAL OF VIDOFLUDIMUS CALCIUM IN PROGRESSIVE MULTIPLE SCLEROSIS

PR Newswire | October 10, 2023

Immunic, Inc. a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive interim data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). The Company believes t...

Read More
news image

Medical

CONVATEC SELECTS VEEVA VAULT CDMS FOR STUDY OF BIOMARKERS IN WOUND INFECTIONS

Veeva Systems | September 24, 2021

Veeva Systems announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic disease, has selected Veeva Vault CDMS , which will provide electronic data entry ( EDC ), coding and data cleaning for its upcoming study on wound infection detection. ConvaTec and its partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers:...

Read More
news image

LILLY BEGINS WORLD'S FIRST STUDY OF A POTENTIAL COVID-19 ANTIBODY TREATMENT IN HUMANS

Lilly | June 01, 2020

Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in just three months after AbCellera and the Vaccine Research Center at t...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us